## Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:30 - 10:00 AM</td>
<td>Welcome</td>
</tr>
<tr>
<td>10:00 - 11:00 AM</td>
<td>Panel: VC Criteria for Investment</td>
</tr>
<tr>
<td>11:00 - 12:00 PM</td>
<td>Panel: Biopharma Criteria for Licensing</td>
</tr>
<tr>
<td>12:00 - 1:00 PM</td>
<td>Lunch &amp; Panel: Federal Government Resources</td>
</tr>
<tr>
<td>1:00 - 3:30 PM</td>
<td>Drug Candidate Presentations</td>
</tr>
<tr>
<td>3:30 - 5:00 PM</td>
<td>Cocktail Reception</td>
</tr>
</tbody>
</table>

## Speakers

### Welcome
- **Michael Nathanson, JD, LLM**  
  Chairman, CEO, & President  
  The Colony Group
- **Scott Memmott, JD**  
  Partner, Healthcare Practice  
  Morgan, Lewis & Bockius

### VC Panel
- **Louis Beardell, Jr., JD**  
  Partner, Intellectual Property  
  Morgan, Lewis & Bockius
- **Brian Gallagher, PhD**  
  Partner  
  SR One
- **Neil Exter**  
  Partner  
  Third Rock Ventures
- **Michael Gutch, PhD, MBA**  
  Managing Director  
  MedImmune Ventures

### BioPharma Panel
- **Lauren Abrey, MD**  
  Global Development Team Lead  
  Genentech / Roche
- **Joanne Smith-Farrell, PhD**  
  Head of Strategic Transactions  
  Pfizer
- **Skip Irving, MBA**  
  Partner and Managing Director  
  Health Advances
- **Andrew Whitney, JD**  
  Associate, Litigation and Intellectual Property  
  Morgan, Lewis & Bockius

### Federal Government Resources Panel
- **Stephanie Fertig, MBA**  
  Research Project Manager  
  NIH/NINDS
- **Jane Fountain, PhD**  
  Program Director, Extramural Research Program  
  NIH/NINDS

### Drug Candidate Presentations

#### Overview of Glioblastoma
- **Skip Irving, MBA**  
  Partner and Managing Director  
  Health Advances
- **Charles Conrad, MD**  
  University of Texas MD Anderson Cancer Center  
  WP1122: Anti-glycolysis Agent
- **Lawrence Lamb, Jr., PhD**  
  University of Alabama at Birmingham  
  Chemotherapy-resistant Cell Therapy
- **Duane Mitchell, MD, PhD**  
  Duke University  
  Therapeutic Vaccines Targeting CMV Antigens
- **John Sampson**  
  Duke University  
  EGFRvIII-targeted BiTEs (Bispecific T-cell Engagers)